SAB Biotherapeutics SABS Q4 2024 Annual earnings
Reported March 28, 2025 · Before market open
Revenue$100.0KMiss by $20.0K
EPS-$1.23Miss by $0.07
Revenue estimate$120.0K
EPS estimate-$1.16
Next report
Aug 6, 2026 (In 1 week)Revenue estimate$125.0K
EPS estimate-$0.29
Versus estimates
Revenue
Q4 2024$100.0KMiss by $20.0K
Diluted EPS
Ask the moment SAB Biotherapeutics reports.
Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.
Connect your AI
Claude
Questions, answered.
- When did SAB Biotherapeutics report Q4 2024 earnings?
- SAB Biotherapeutics (SABS) reported Q4 2024 earnings on March 28, 2025 before market open.
- What were SAB Biotherapeutics's Q4 2024 revenue and EPS?
- SAB Biotherapeutics reported revenue of $100.0K and eps of $-1.23 for Q4 2024.
- Did SAB Biotherapeutics beat estimates in Q4 2024?
- Revenue missed the consensus estimate of $120.0K by $20.0K. EPS missed the consensus estimate of $-1.16 by $0.07.
- Where can I find SAB Biotherapeutics's Q4 2024 SEC filings?
- You can read the 10-K periodic report (0000950170-25-046994) directly on SEC EDGAR. The filing index links above go to sec.gov.